---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-215720"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2026-05-11T23:59:59+00:00"
generated_at: "2026-05-14T18:54:03.490700+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Dyne Q1 net loss $120.9M; BLA for z-rostudirsen on track for Q2 2026

## Summary
- Net loss of $120.9M ($0.73 per share) vs $115.4M ($1.05) in Q1 2025.
- Cash and marketable securities $972.2M; expected to fund operations into Q1 2028.
- R&D expenses $100.9M (down from $106.4M); G&A $24.4M (up from $15.9M) due to launch prep.
- Positive pre-BLA meeting with FDA; BLA submission for z-rostudirsen in exon 51 DMD on track for Q2 2026.
- ACHIEVE trial enrollment target of 60 participants reached; Phase 3 HARMONIA trial for z-basivarsen in DM1 initiated.

## SEC filing metadata
- accession: 0001193125-26-215720
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2026-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312526215720/0001193125-26-215720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312526215720/dyn-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-215720
- JSON: https://secwatch.observer/filing/0001193125-26-215720.json
- Plain text: https://secwatch.observer/filing/0001193125-26-215720.txt

## Source-grounded claims
- claim_id: b5f54fd623b59b784cb5a7db1345a9854d3c206c
  claim: Dyne Therapeutics, Inc. reported financial results for the first quarter of 2026.
  evidence_excerpt: Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today reported financial results for the first quarter of 2026 and recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000119312526215720/0001193125-26-215720-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.